Mason Hayes & Curran LLP | Ireland, United Kingdom | 1 Sep 2023
The Irish High Court granted an injunction in February 2023 in favour of Bristol-Myers Squibb (BMS), a global biopharmaceutical company, against Teva…
Lexology PRO | United Kingdom | 23 Nov 2022
An in-house lawyer at a drugmaker since bought out by Advanz Pharma allowed the company’s most senior staff to hold meetings without strictly abiding by certain compliance rules, counsel to the UK's Competition and Markets Authority has claimed.
Lexology PRO | European Union, Italy, Netherlands, etc. | 19 Jul 2021
The Dutch competition authority has fined Leadiant Biosciences €17.9 million for charging excessively high prices for a drug used to treat a rare genetic metabolic disorder, marking the first time it has ever imposed a penalty for such an infringement.
Lexology PRO | United Kingdom | 15 Jul 2021
The UK’s Competition and Markets Authority has fined four drugmakers over £266 million for inflating the price of a life-saving drug by over 10,000% and preventing the entry of competing medicines.
Pinsent Masons | United Kingdom | 19 May 2021
The 'doctrine of equivalents' (ie, the principle that a patent may be infringed by a product or process which is considered equivalent to that…
PRO Compliance | USA | 11 Jun 2020
A coalition of 51 US states and territories have filed their third sweeping antitrust lawsuit against the generic pharmaceuticals industry, alleging a massive conspiracy to fix prices for topical skin treatments.
Hogan Lovells | Italy | 16 Oct 2019
Where a known compound in an invention is claimed to treat a disease (second medical use patents), must the patent prove that a compound cures the…
AA Thornton IP LLP | United Kingdom | 20 Nov 2018
The Supreme Court of the United Kingdom has now released their long-awaited decision relating to the tests for sufficiency and infringement for second…
Freshfields Bruckhaus Deringer | European Union, United Kingdom | 14 Nov 2018
The UK Supreme Court handed down its much anticipated judgment in the Warner-Lambert v Mylan and Actavis (Lyrica) case today (https://www…
Knobbe Martens | USA | 11 Sep 2018
Objective indicia of nonobviousness cannot be dismissed merely because all the ingredients in a formulation were generally known and nothing prevented…